Prevymis is a medication used to prevent cytomegalovirus (CMV) infection and disease in adult patients who have received a stem cell transplant [1][2]. It is taken orally [1].
How does Prevymis work?
Prevymis, also known by its generic name letermovir, is an antiviral medication. It works by inhibiting the CMV DNA terminase complex, which is essential for viral DNA replication [1][3]. This action prevents the virus from multiplying and spreading [3].
What is Prevymis prescribed for?
The primary use of Prevymis is prophylaxis for cytomegalovirus (CMV) infection and disease in adult recipients of an allogeneic stem cell transplant [1][2]. This means it is given to prevent CMV from causing illness in individuals whose immune systems are compromised after receiving stem cells from a donor [2].
When does the patent for Prevymis expire?
Information regarding the specific patent expiration dates for Prevymis can be found on DrugPatentWatch.com [4]. Patent exclusivity is crucial for drug manufacturers, impacting market competition and the potential for generic versions [4].
What are the potential side effects of Prevymis?
Common side effects reported with Prevymis include diarrhea, nausea, vomiting, and taste disturbances [1]. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider [1].
Who manufactures Prevymis?
Prevymis is manufactured by Merck & Co., Inc. [1].